Mehabe score: 5 G Factor: 6 Piotski Score: 8 The stock has a rating . The mehabe team score is reflective of its fundamental and technical merits. A rating above 8 is considered good buy. The stock has a G-Factor of 6 and Piotski score of 8.
Description
Abbott India is engaged in the business of manufacturing, selling, distribution and marketing of Pharmaceuticals.Site:ABBOTINDIAMain Symbol:ABBOTINDIA
Stock trades at 17925.0, above its 50dma 17187.87. It also trades above its 200dma 15956.82. The stock remains bullish on techicals
The 52 week high is at 19994.70 and the 52week low is at 13959.80
Price Chart
P/E Chart
Sales and Margin
Strengths
– is almost debt free.
– has delivered good profit growth of 22.02% CAGR over last 5 years
– has a good return on equity (ROE) track record: 3 Years ROE 26.24%
– has been maintaining a healthy dividend payout of 68.29%
Weakness
– Stock is trading at 14.64 times its book value
-The company has delivered a poor sales growth of 10.51% over past five years.
Competition
– The industry trades at a mean P/E of 65.3x. Novartis India trades at the industry’s max P/E of 111.56x. ABBOTINDIA trades at a P/E of 55.1x
– Industry’s mean G-Factor is 4.1 while the mean Piotski score is 8.0. ABBOTINDIA has a G-Factor of 6 and Piotski scoreof 8.
– Average 1 month return for industry is 3.6%. The max 1- month return was given by Sanofi India: a return of 13.96 %
Quarterly Results
Sales for period ended Jun 2021 is Rs 1218.0 cr compared to Rs 1064.0 cr for period ended Jun 2020, a rise of 14.5%
Operating Profits reported at Rs 265.0 cr for period ended Jun 2021 vis-vis 233.0 for period ended Jun 2020 .
Operating Margins contracted -14.2 bps for period ended Jun 2021 vis-vis Jun 2020 .
The EPS for Jun 2021 was Rs 92.13 compared to Rs 71.75 for previous quarter ended Mar 2021 and Rs 84.87 for Jun 2020
Profit & Loss Statement
Profit&Loss Comments
Company reported sales of Rs 4464.0 cr for period ended TTM vis-vis sales of Rs 4310.0 cr for the period ended Mar 2021, a growth of 3.4%. The 3 year sales cagr stood at 6.7%.
Net Profit reported at Rs 706.0 cr for period ended TTM vis-vis sales of Rs 691.0 cr for the period ended Mar 2021, rising 2.1%.
Company recorded a healthy Net Profit CAGR of 16.2% over the last 3 years
Balance Sheet Statement
Cash Flow Statement
Cash Flow comments
CashFlow from operating activities was positive.
CashFlow from operating activities: Rs 727.0 cr for period ended Mar 2021 vis-vis Rs 626.0 cr for period ended Mar 2020
Sales Growth
Profit Growth Statement
Profit Growth Statement
Stock Price CAGR
Return of Equity
General Comments
– The company has had stable/constant Return on Equity (RoE) metric. The RoE on Last Year basis was 27.0% compared to 26.0% over the last 3 Years. – The stock has given a return of 11% on a 1 Year basis vis-vis a return of 31% over the last 3 Years. – The compounded sales growth on a TTM bassis is 5% vis-vis a compounded sales growth of 9% over the last 3 Years. – The compounded profit growth on a TTM basis is 16% vis-vis a compounded profit growth of 20% over the last 3 Years.
Ratios
Shareholding Pattern
– FII shareholding has remained largely constant. The Jun 2021 fii holding stood at 0.25% vis-vis 1.01% for Mar 2021 – Public shareholding has remained largely constant. The Jun 2021 public holding stood at 18.03% vis-vis 18.47% for Mar 2021
Conclusion
– is almost debt free.
– has delivered good profit growth of 22.02% CAGR over last 5 years
– has a good return on equity (ROE) track record: 3 Years ROE 26.24%
– has been maintaining a healthy dividend payout of 68.29% – Stock is trading at 14.64 times its book value
-The company has delivered a poor sales growth of 10.51% over past five years.
